These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Immunology. Flu antibodies stir new hope for treatment, vaccine. Leslie M Science; 2009 Feb; 323(5918):1160. PubMed ID: 19251602 [No Abstract] [Full Text] [Related]
24. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice. Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973 [TBL] [Abstract][Full Text] [Related]
25. Influenza vaccine response following its simultaneous application with BCG 1st report. Zykov MP; Raphaelskaya TI Z Erkr Atmungsorgane; 1981; 156(3):203-11. PubMed ID: 7293275 [TBL] [Abstract][Full Text] [Related]
26. A novel synthetic adjuvant effectively enhances the immunogenicity of the influenza vaccine. Segura-Velázquez R; Pérez-Torres A; Rosas G; Toledo A; Restelli M; Acosta E; Corral R; Rosetti F; Fragoso G; Grinstein S; Sciutto E Vaccine; 2006 Feb; 24(8):1073-80. PubMed ID: 16202486 [TBL] [Abstract][Full Text] [Related]
28. Attenuated ts-recombinants of influenza A/USSR/77 (H1N1) virus obtained by crossing with the cold-adapted donor A/Leningrad/134/57 (H2N2) virus. Polezhaev FI; Garmashova LM; Koval TA; Taranova GP; Topuriya NV; Aleksandrova GI Acta Virol; 1982 Jul; 26(4):221-6. PubMed ID: 6127928 [TBL] [Abstract][Full Text] [Related]
29. Search for optimal scheme for administering live allantoic influenza vaccine. Zykov MP; Shaposhnikova RP; Vasil'eva RI; Subbotina TI; Rudenko LG; Gordon MA; Vakin VS J Hyg Epidemiol Microbiol Immunol; 1983; 27(4):419-24. PubMed ID: 6663074 [TBL] [Abstract][Full Text] [Related]
30. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Brett IC; Johansson BE Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702 [TBL] [Abstract][Full Text] [Related]
31. Fusing subunit antigens to interleukin-2 and encapsulating them in liposomes improves their antigenicity but not their protective efficacy. Wales JR; Baird MA; Davies NM; Buchan GS Vaccine; 2005 Mar; 23(17-18):2339-41. PubMed ID: 15755624 [TBL] [Abstract][Full Text] [Related]
32. The influence of the host cell on standardisation of influenza vaccine potency. Wood JM; Dunleavy U; Newman RW; Riley AM; Robertson JS; Minor PD Dev Biol Stand; 1999; 98():183-8; discussion 197. PubMed ID: 10494972 [TBL] [Abstract][Full Text] [Related]
33. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity. Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633 [TBL] [Abstract][Full Text] [Related]
35. Immunogenic and isotype-specific responses to Russian and US cold-adapted influenza a vaccine donor strains A/Leningrad/134/17/57, A/Leningrad/134/47/57, and A/Ann Arbor/6/60 (H2N2) in mice. Wareing MD; Watson JM; Brooks MJ; Tannock GA J Med Virol; 2001 Sep; 65(1):171-7. PubMed ID: 11505460 [TBL] [Abstract][Full Text] [Related]
38. Monoclonal antibodies for the control of influenza virusvaccines. van de Donk HJ; de Jong JC; van Olderen MF; Osterhaus AD Dev Biol Stand; 1984; 57():251-5. PubMed ID: 6526141 [TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. Tanzi E; Esposito S; Bojanin J; Amendola A; Trabattoni D; Pariani E; Pinzani R; Zanetti A; Principi N J Med Virol; 2006 Apr; 78(4):440-5. PubMed ID: 16482542 [TBL] [Abstract][Full Text] [Related]
40. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice. Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]